iMmune SignAtures and Clinical outComes in AP

(MoSAIC Trial)

Recruiting at 4 trial locations

Overseen By Samantha Terhorst, MS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Ohio State University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

198 Participants Needed

Trial Summary

What is the purpose of this trial?

The MoSAIC study is a prospective, observational study designed to develop an early prediction tool for severe acute pancreatitis (SAP) and define a distinct immunologic profile compared to moderate acute pancreatitis (MAP). The aims are to validate a new multi-cytokine panel for early prediction of SAP and to identify the specific immune cells that correspond with cytokine signatures in early acute pancreatitis to characterize the immune pathways driving the development of SAP. Participants will provide blood samples and complete patient surveys and interviews within 36 hours of hospital presentation, at 48 hours, and hospital day 7 (if admitted). Data on hospital stay, medical history, clinical course, and severity of disease will be collected.

Eligibility Criteria

Inclusion Criteria

Age 18-75 years at the time of enrollment

Diagnosis of acute pancreatitis (AP) according to the revised Atlanta criteria (see definition below)

Participant is approached by the research team within 36 hours of presentation to the hospital

Treatment Details

Participant Groups

Group I: Acute Pancreatitis Experimental Treatment 1 Intervention

Patients meeting Revised Atlanta Criteria for diagnosis of acute pancreatitis

Who Is Running the Clinical Trial?

Ohio State University

Lead Sponsor

Trials

891

Recruited

2,659,000+

Benaroya Research Institute

Collaborator

Trials

50

Recruited

12,300+

University of Pittsburgh

Collaborator

Trials

1,820

Recruited

16,360,000+

University of Southern California

Collaborator

Trials

956

Recruited

1,609,000+

University of Illinois at Chicago

Collaborator

Trials

653

Recruited

1,574,000+